FindMyKOL
Clinical trialNCT03715933RecruitingPhase 1Interventional

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

NCT03715933 is a phase 1 interventional trial sponsored by Inhibrx Biosciences, Inc. As of 21 Nov 2026, it is recruiting participants. It studies Bevacizumab, Fluorouracil, INBRX-109, Irinotecan and 5 more drugs in Colorectal Adenocarcinoma and Ewing Sarcoma. The registry lists an enrollment of 411 participants at 37 sites in 6 countries. The registry lists a start date of 8 Oct 2018 and a primary completion date of 31 Dec 2028. 5 of its registered investigators have a FindMyKOL profile.

SponsorInhibrx Biosciences, IncEnrollment411Colorectal AdenocarcinomaEwing Sarcoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03715933
FieldValue
Registry IDNCT03715933
StatusRecruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorInhibrx Biosciences, Inc
Enrollment411
Registered sites37
Countries6
ConditionsColorectal Adenocarcinoma and Ewing Sarcoma
DrugsBevacizumab, Fluorouracil, INBRX-109, Irinotecan, Leucovorin, Temozolomide, Tipiracil / trifluridine, Carboplatin and Pemetrexed
Start8 Oct 2018
Primary completion31 Dec 2028
Study completion30 Jun 2029
Last update posted8 Sept 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

37 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Arizona, United States1 site
  • Honorhealth Research Institute

    Scottsdale

    Completed
California, United States7 sites, 6 recruiting
  • Precision Nextgen Oncology and Research

    Beverly Hills

    Kamalesh Sankhala, MD
    Recruiting
  • City of Hope

    Duarte

    Marwan Fakih, MD
    Recruiting
  • Valkyrie Clinical Trials

    Los Angeles

    David Berz, MD
    Recruiting
  • Children's Hospital of Orange County-Rady Children's Health

    Orange

    Dr. Elyssa Rubin, MD
    Recruiting
  • University of California, San Diego (ucsd) - Moores Cancer Center

    San Diego

    Withdrawn
  • University of California, San Francisco (ucsf)

    San Francisco

    Varun Monga, MD
    Recruiting
  • Sarcoma Oncology Center

    Santa Monica

    Sant P Chawla, MD
    Recruiting
Colorado, United States1 site, 1 recruiting
  • University of Colorado Hospital

    Aurora

    Christopher Lieu, MD
    Recruiting
Georgia, United States1 site, 1 recruiting
  • Emory University - Winship Cancer Institute

    Atlanta

    Olatunji Alese, MD
    Recruiting
Illinois, United States1 site
  • the University of Chicago

    Chicago

    Completed
Michigan, United States2 sites, 2 recruiting
  • University of Michigan

    Ann Arbor

    Rashmi Chugh, MD
    Recruiting
  • Start Midwest Michigan, Pc

    Grand Rapids

    Nehal Lakhani, MD
    Recruiting
New York, United States1 site, 1 recruiting
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York

    Emily Slotkin, MD
    Recruiting
Ohio, United States2 sites, 1 recruiting
  • Cincinnati Children's Hospital Medical Center

    Cincinnati

    Michael D Deel, MD
    Recruiting
  • Cleveland Clinic

    Cleveland

    Completed
Oregon, United States1 site, 1 recruiting
  • Oregon Health & Science University

    Portland

    Michael Heinrich, MD
    Recruiting
Pennsylvania, United States2 sites, 2 recruiting
  • Children's Hospital of Philadelphia- Center for Childhood Cancer Research

    Philadelphia

    Theodore Laetsch, MD
    Recruiting
  • University of Pennsylvania Abramson Cancer Center

    Philadelphia

    Lee Hartner, MD
    Recruiting
Tennessee, United States1 site, 1 recruiting
  • Vanderbilt University School of Medicine

    Nashville

    Elizabeth Davis, MD
    Recruiting
Texas, United States2 sites, 1 recruiting
  • Ut Md Anderson Cancer Center

    Houston

    David Hong, MD
    Recruiting
  • Next Oncology

    San Antonio

    Completed
Virginia, United States2 sites, 2 recruiting
  • University of Virginia

    Charlottesville

    Ludimila Cavalcante, MD
    Recruiting
  • Next Oncology - Virginia

    Fairfax

    Alexander Spira, MD
    Recruiting
United Kingdom4 sites, 4 recruiting
  • Great North Children's Hospital

    London

    Quentin Campbell-Hewson, MD
    Recruiting
  • the Royal Marsden Nhs Foundation Trust

    London

    Andrea Napolitano, MD
    Recruiting
  • University College London Hospital

    London

    Sandra Strauss, MD
    Recruiting
  • Royal Manchester Children's Hospital

    Manchester

    Bernadette Maria Dymphna Brennan
    Recruiting
Spain3 sites, 3 recruiting
  • Hospital Universitario Vall D'Hebron

    Barcelona

    Elena Elez, MD
    Recruiting
  • Hospital de la Santa Creu I Sant Pau

    Barcelona

    Ana Sebio Garcia, MD
    Recruiting
  • Hospital Clinico San Carlos

    Madrid

    Antonio Casado Herraez
    Recruiting
France2 sites, 2 recruiting
  • Centre Leon Berard

    Lyon

    Mehdi Brahmi, MD
    Recruiting
  • Gustave Roussy

    Villejuif

    Pablo Berlanga, MD
    Recruiting
Italy2 sites, 2 recruiting
  • la Fondazione E L'Istituto Di Candiolo

    Candiolo

    Sandra Aliberti, MD
    Recruiting
  • Fondazione Irccs Istituto Nazionale Dei Tumori

    Milan

    Roberto Luksch, MDSalvatore Provenzano, MD
    Recruiting
Netherlands2 sites, 2 recruiting
  • University Medical Center Groningen

    Groningen

    Jacco de Haan, MD
    Recruiting
  • Academisch Ziekenhuis Leiden

    Leiden

    André (Hans) Gelderblom, MD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichigan: 2 sites, 2 recruitingMI2New York: 1 site, 1 recruitingNY1MassachusettsMARhode IslandRIOregon: 1 site, 1 recruitingOR1IdahoIDSouth DakotaSDIowaIAIllinois: 1 siteIL1IndianaINOhio: 2 sites, 1 recruitingOH2Pennsylvania: 2 sites, 2 recruitingPA2New JerseyNJConnecticutCTCalifornia: 7 sites, 6 recruitingCA7NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginia: 2 sites, 2 recruitingVA2MarylandMDDelawareDEArizona: 1 siteAZ1UtahUTColorado: 1 site, 1 recruitingCO1KansasKSArkansasARTennessee: 1 site, 1 recruitingTN1North CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 1 site, 1 recruitingGA1HawaiiHITexas: 2 sites, 1 recruitingTX2FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Questions about NCT03715933

Each answer restates registry values shown on this page.

What is NCT03715933?

NCT03715933 is a phase 1 interventional trial sponsored by Inhibrx Biosciences, Inc. It studies Bevacizumab, Fluorouracil, INBRX-109, Irinotecan and 5 more drugs in Colorectal Adenocarcinoma and Ewing Sarcoma.

Is NCT03715933 recruiting?

As of 21 Nov 2026, it is recruiting participants. 32 of its 37 sites list their own status as recruiting.

Who leads NCT03715933?

The registry names Clinical Lead (study director, Inhibrx Biosciences, Inc) as the overall official.

Where does NCT03715933 run?

The registry lists 37 sites in 6 countries. Most sites are in these countries: United States (24), United Kingdom (4) and Spain (3).

Which drugs does NCT03715933 study?

The registered drug and biological interventions are Bevacizumab, Fluorouracil, INBRX-109, Irinotecan, Leucovorin, Temozolomide, Tipiracil / trifluridine, Carboplatin and Pemetrexed.

When is NCT03715933 expected to complete?

The registry lists a primary completion date of 31 Dec 2028 and a study completion date of 30 Jun 2029. The sponsor last updated the record on 8 Sept 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.